Indivior PLC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ

3 Aug 2026

INDV

10-Q: Indivior Pharmaceuticals Reports Strong Q2 2026 Results, Merger Progress

Indivior Pharmaceuticals announced robust Q2 2026 financial results with a 14% revenue increase, driven by SUBLOCADE, and significant progress on its merger with Supernus Pharmaceuticals.

NASDAQ

30 Oct 2025

INDV

Indivior PLC

10-Q: Indivior Q3 Net Income Soars Amid Strategic Restructuring

Indivior PLC reported a significant increase in net income for Q3 2025, driven by strong SUBLOCADE sales and ongoing strategic restructuring initiatives.

NASDAQ

31 Jul 2025

INDV

Indivior PLC

10-Q: Indivior Reports Q2 Profit Amid Strong SUBLOCADE Growth and Strategic Nasdaq Shift

Indivior PLC reported a significant turnaround to net income in the second quarter of 2025, driven by robust SUBLOCADE sales and improved gross margins, despite ongoing litigation challenges and a one-time UK tax settlement.

NASDAQ

1 May 2025

INDV

Indivior PLC

10-Q: Indivior PLC Reports Q1 2025 Results: Revenue Declines Amidst Increased Competition

Indivior PLC's Q1 2025 net revenue decreased by 6% year-over-year to $266 million, primarily due to increased competition affecting SUBOXONE Film sales in the U.S.